{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.8","value":"5.76"},{"groupId":"OG001","spread":"27.1","value":"13.9"},{"groupId":"OG002","spread":"16.9","value":"15.2"},{"groupId":"OG003","spread":"20.7","value":"21.3"},{"groupId":"OG004","spread":"36.0","value":"15.1"},{"groupId":"OG005","spread":"40.4","value":"13.2"},{"groupId":"OG006","spread":"25.1","value":"13.5"},{"groupId":"OG007","spread":"42.8","value":"15.8"},{"groupId":"OG008","spread":"35.8","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"38"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on trametinib plasma concentrations by using non-compartmental methods. The average steady state plasma concentration (Cavg) of trametinib was calculated as the ratio of area under the curve (AUC)/tau, where tau = 24 h for trametinib.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants treated with trametinib 0.0125 mg/kg/day","id":"OG000","title":"Part A - TMT 0.0125 mg/kg/Day"},{"description":"Participants treated with trametinib 0.025 mg/kg/day","id":"OG001","title":"Part A - TMT 0.025 mg/kg/Day"},{"description":"Participants under 6 years of age treated with trametinib 0.032 mg/kg/day","id":"OG002","title":"Part A - TMT 0.032 mg/kg/Day"},{"description":"Participants treated with trametinib 0.04 mg/kg/day","id":"OG003","title":"Part A - TMT 0.04 mg/kg/Day"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"OG004","title":"Part B - Neuroblastoma"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"OG005","title":"Part B - LGG Fusion"},{"description":"Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day","id":"OG006","title":"Part B - NF-1 With PN"},{"description":"Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day","id":"OG007","title":"Part B - BRAF V600 Mutant Solid Tumor"},{"description":"Participants (all tumor types in Part B) treated with trametinib 0.025 mg/kg/day","id":"OG008","title":"Part B - All Tumor Types TMT 0.025 mg/kg/Day"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All subjects who received at least one dose of trametinib in Part A and B and provided an evaluable PK profile with a value for the outcome measure","reportingStatus":"POSTED","timeFrame":"pre dose, 1, 2, 4, 7, 10 and 24 hours post trametinib dose on Cycle 1 Day 15. The duration of 1 cycle was 28 days.","title":"Average Steady State Plasma Concentration (Cavg) of Trametinib When Administered Alone (Monotherapy)","type":"PRIMARY","unitOfMeasure":"ng/mL"}